Prot# D16900C00053: PRESERVED-HF: Effects of Dapaglifloxin on Biomarkers, Symtoms and Functional Status in Patients with Type 2 Diabetes or Pre-Diabetes, and Preserved Ejection Fraction Heart Failure (PRESERVED-HF TRIAL)

Project: Research project

Project Details

StatusFinished
Effective start/end date5/22/17 → 5/22/23

Funding

  • Saint Luke's Hospital of Kansas City (Prot# D16900C00053 // Prot# D16900C00053)
  • AstraZeneca Pharmaceuticals LP (Prot# D16900C00053 // Prot# D16900C00053)